Objective: The aim of this study was to describe the current status of aspirin use and the demographic characteristics of patients on aspirin for primary and secondary prevention of cardiovascular diseases.
Methods: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) trial was a multicenter, cross-sectional, and observational study conducted in Turkey. The study was planned to include 5000 patients from 14 cities in Turkey. The data were collected at one visit, and the current clinical practice regarding aspirin use was evaluated (ClinicalTrials.gov number NCT03387384).
Results: The study enrolled all consecutive patients who were admitted to the outpatient cardiology clinics from March 2018 until June 2018. Patients should be at least 18 years old, have signed written informed consent, and on aspirin (80-325 mg) therapy within the last 30 days. Cardiologists from the hospital participates in the study. Patients were divided into 2 categories according to presence or absence of atherosclerotic cardiovascular disease, namely secondary prevention group and primary prevention group, respectively. The appropriate use of aspirin in the primary and secondary prevention groups was assessed according to the European Society of Cardiology guidelines and US Preventive Services Task Force. The patients' gastrointestinal bleeding risk factors and colorectal cancer risk were evaluated.
Conclusion: The ASSOS registry will be the most comprehensive and largest study in Turkey evaluating the appropriateness of aspirin use. The results of this study help understand the potential misuse of aspirin in a real-world setting.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287439 | PMC |
| http://dx.doi.org/10.14744/AnatolJCardiol.2018.47587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment with mannose oligosaccharides reverses the intestinal injury in the acetylsalicylic acid-treated rat model.
Pol J Vet Sci
June 2024
College of Biological Engineering, Henan University of Technology, Zhengzhou, China.
Mannose oligosaccharide (MOS) has been shown to promote animal growth, maintain intestinal health, and activate the intestinal immune system. However, the question of whether MOS can stimulate the immune system and alleviate acetylsalicylic acid (ASA)-induced gut damage remains unresolved. The purpose of this study was to investigate the impact of MOS pretreatment on the immunological and anti-inflammatory capabilities of rats with ASA-induced intestinal injury.
View Article and Find Full Text PDFAn intimal-lumen model in a microfluidic device: potential platform for atherosclerosis-related studies.
Lab Chip
December 2024
Queensland Micro- and Nanotechnology, Griffith University, Nathan, Queensland 4111, Australia.
Atherosclerosis is a chronic inflammatory vascular disorder driven by factors such as endothelial dysfunction, hypertension, hyperlipidemia, and arterial calcification, and is considered a leading global cause of death. Existing atherosclerosis models have limitations due to the absence of an appropriate hemodynamic microenvironment and interspecies differences . Here, we develop a simple but robust microfluidic intimal-lumen model of early atherosclerosis using interconnected dual channels for studying monocyte transmigration and foam cell formation at an arterial shear rate.
View Article and Find Full Text PDFA Case of Refractory Kawasaki Disease With Yersinia pseudotuberculosis Infection Successfully Treated With Cefotaxime Following Immunosuppressive Therapy.
Cureus
November 2024
Department of Pediatrics, Japanese Red Cross Wakayama Medical Center, Wakayama, JPN.
Kawasaki disease (KD) is a vasculitis mainly affecting children under five, with symptoms such as persistent fever, rash, red lips, strawberry tongue, conjunctivitis, and swollen hands and feet. Diagnosis is based on a fever lasting over five days plus at least four of these symptoms. Treatment includes intravenous immunoglobulin (IVIG) and aspirin to reduce complications, especially coronary artery issues.
View Article and Find Full Text PDFCurrent trends for venous thromboembolic prophylaxis for hip arthroscopy: a modified Delphi and nominal group technique consensus study.
J Hip Preserv Surg
July 2024
American Hip Institute Research Foundation, 999 E Touhy Ave, Chicago, IL 60018, USA.
Article Synopsis
- * A study surveyed 35 experienced hip surgeons, revealing that 91.4% use chemoprophylaxis, primarily aspirin, with varying durations suggested, mostly between 2 to 4 weeks post-surgery.
- * While most experts agree on the importance of VTE prophylaxis, there is no consensus on the best duration for treatment or recommendations regarding stopping oral contraceptives and smoking before the surgery.
Deep vein thrombosis prophylaxis in patients who undergo knee arthroscopy: a systematic review.
Knee Surg Relat Res
December 2024
Department of Orthopaedic Surgery and Rehabilitation, Loyola University Medical Center, 2160 S First Avenue, Maguire Building, Suite 1700, Maywood, IL, 60153, USA.
Background: Knee arthroscopy is one of the most common procedures performed by orthopedic surgeons. A potentially life-threatening complication following this procedure is deep vein thrombosis (DVT). DVT prophylaxis can be obtained both mechanically (e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!